Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

Affiliations

• ¹ Charles River Laboratories, Cleveland, OH, USA.
• ² Safety Pharmacology, Bayer AG, Wuppertal, Germany.
• ³ Sophion Bioscience A/S, Ballerup, Denmark.
• ⁴ Nanion Technologies GmbH, Munich, Germany.
• ⁵ Global Safety Pharmacology, GlaxoSmithKline PLC, Collegeville, PA, USA.
• ⁶ Drug Safety Research & Development, Pfizer, Groton, CT, USA.
• ⁷ Integrated Drug Discovery, High Content Biology Unit, Sanofi R&D, Vitry-Sur-Seine, France.
• ⁸ Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, Astra Zeneca, Cambridge, UK.
• ⁹ B'SYS GmbH, Witterswil, Switzerland.
• ¹⁰ Discovery Toxicology, Bristol-Myers Squibb Company, Princeton, NJ, USA.
• ¹¹ Eurofins Discovery, St. Charles, MO, USA.
• ¹² Merck & Co., Inc., Kenilworth, NJ, USA.
• ¹³ Metrion Biosciences Ltd., Cambridge, UK.
• ¹⁴ Nanion Technologies, Livingston, NJ, USA.
• ¹⁵ Nanion Technologies Japan K.K., Shinjyuku-ku, Tokyo, Japan.
• ¹⁶ Natural and Medical Science Institute at the University of Tübingen, Reutlingen, Germany.
• ¹⁷ Northwestern Feinberg School of Medicine, Chicago, IL, USA.
• ¹⁸ Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
• ¹⁹ Novoheart, Vancouver, BC, Canada.
• ²⁰ Health and Environmental Sciences Institute, Washington, DC, USA. [email protected].
• ²¹ AbbVie, Chicago, IL, USA.